Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Compare dentists to save

2018-08-17 ntnews.com.au
CONCERNS about costs deter Australians from visiting dentists and those that do often feel too disempowered to ask for a better deal, one industry professional says.
ALADA

55
Senseonics Holdings Inc. (SENS) CEO Tim Goodnow on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha - 2
Good day, and welcome to the Senseonics Second Quarter 2018 Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.
ALADA SENS

0
Experts question benefits of fluoride-free toothpaste

2018-08-07 nzherald.co.nz
Dental health experts worry that more people are using toothpaste that skips the most important ingredient — fluoride — and leaves them at a greater risk of cavities.
ALADA

0
'Disgusted': More than 30,000 school children illegally X-rayed

2018-08-03 smh.com.au
More than 30,000 school children across NSW have been illegally X-rayed in an extraordinary dental practice that continues to operate despite concerns being raised with health and education departments.
ALADA

73
OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity

2018-06-11 globenewswire
MIAMI, June 11, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced it has completed enrollment of 110 subjects in a Phase 2b dose escalation trial of OPK88003 to treat type 2 diabetes and obesity. OPK88003 is a once weekly injectable oxyntomodulin medicine with GLP-1 and glucagon dual agonist activity. The primary efficacy endpoint is the reduction of HbA1c levels over a 30-week period; weight loss and improvement of blood lipid profiles are secondary endpoints.
ALADA OPK

0
Mental health support lacking in US diabetes care

2018-05-17 channelnewsasia
(Reuters Health) - Most of the top diabetes treatment centers in the U.S. provide experts in hormonal disease, diet and nutrition and diabetes education as part of normal care, but mental health support is still not standard, researchers say.
ALADA

0
New directory lists mental health providers with diabetes expertise - Channel NewsAsia

2018-05-07 channelnewsasia
REUTERS: The American Diabetes Association and the American Psychological Association have created a new public directory of mental health providers with diabetes-specific education or experience, the organizations announced recently.
ALADA

4
Novo Nordisk A/S (NVO) Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Good day and welcome to the Quarter One 2018 Novo Nordisk A/S Conference Call. Today's conference is being recorded. At this time I would like to turn the conference over to Lars Fruergaard Jørgensen, CEO. Please go ahead, sir.
ALADA DB

73
OPKO Health Enrolls First Patient in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes

2018-03-23 globenewswire
MIAMI, March 23, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) has enrolled the first patient in a Phase 2b dose escalation trial of OPK88003, a once-weekly oxyntomodulin therapy containing dual agonist activity towards GLP-1 and Glucagon receptors, to treat type 2 diabetes and obesity. Based on preclinical and Phase 2 data, the use of once-weekly dual agonists, such as OPK88003, could more effectively improve glucose control, increase weight loss and improve the lipid profile in type 2 diabetics compared to the current GLP—1 therapies on the market.
ALADA OPK

Related Articles

RNVA: Rennova Health Analysis and Research Report

2018-08-18 - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...